Posted by Michael Wonder on 11 Feb 2026
PHARMAC confirms changes to simplify biologic medicine funding criteria
11 February 2026 - PHARMAC has confirmed changes to the Special Authority and Hospital Indication Restrictions criteria for four biologic medicines: infliximab, etanercept, secukinumab, and rituximab.
The changes will reduce administrative workload for clinicians, improve consistency across biologic treatments, and reflect feedback received through consultation.
